The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Ipilimumab and radiation therapy for melanoma brain metastases
Open accessAbstract
Ipilimumab, an antibody that enhances T‐cell activation, may augment immunogenicity of tumor cells that are injured by radiation therapy. We hypothesized that patients with melanoma brain metastasis treated with both ipilimumab and radiotherapy would have improved overall survival, and that the sequence of treatments may affect disease control in the brain. We analyzed the clinical and radiographic records of melanoma patients with brain metastases who were treated with whole brain radiation therapy or stereotactic radiosurgery between 2005 and 2012. The hazard ratios for survival were estimated to assess outcomes as a function of ipilimumab use and radiation type. Seventy patients were identified, 33 of whom received ipilimumab and 37 who did not. The patients who received ipilimumab had a censored median survival of 18.3 months (95% confidence interval 8.1–25.5), compared with 5.3 months (95% confidence interval 4.0–7.6) for patients who did not receive ipilimumab. Ipilimumab and stereotactic radiosurgery were each significant predictors of improved overall survival (hazard ratio = 0.43 and 0.45, with P = 0.005 and 0.008, respectively). Four of 10 evaluable patients (40.0%) who received ipilimumab prior to radiotherapy demonstrated a partial response to radiotherapy, compared with two of 22 evaluable patients (9.1%) who did not receive ipilimumab. Ipilimumab is associated with a significantly reduced risk of death in patients with melanoma brain metastases who underwent radiotherapy, and this finding supports the need for multimodality therapy to optimize patient outcomes. Prospective studies are needed and are underway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Peduzzi, P., Concato, J., Feinstein, A. R., & Holford, T. R. (1995) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(95)00048-8 · Cited by 2,154 · cited 1×
“Due to the small sample size, we only included ipilimumab treatment and type of RT in our main Cox regression model [29].”
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
(2003) · RePEc: Research Papers in Economics · Cited by 1,844
Dewan, M. Z., Galloway, A. E., Kawashima, N., Dewyngaert, J. K., Babb, J. S., Formenti, S. C., & Demaria, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0265 · Cited by 1,678
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70090-6 · Cited by 1,091
Sperduto, P. W., Chao, S. T., Sneed, P. K., Luo, X., Suh, J., Roberge, D., Bhatt, A., Jensen, A. W., Brown, P. D., Shih, H., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.08.025 · Cited by 985
Long, G. V., Trefzer, U., Davies, M. A., Kefford, R. F., Ascierto, P. A., Chapman, P. B., Puzanov, I., Hauschild, A., Robert, C., Algazi, A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70431-x · Cited by 918
Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma
Sampson, J. H., Carter, J. H., Friedman, A. H., & Seigler, H. F. (1998) · Journal of Neurosurgery · doi:10.3171/jns.1998.88.1.0011 · Cited by 560
Determinants of Outcome in Melanoma Patients With Cerebral Metastases
Fife, K. M., Colman, M. H., Stevens, G. N., Firth, I. C., Moon, D., Shannon, K. F., Harman, R., Petersen-Schaefer, K., Zacest, A. C., Besser, M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.140 · Cited by 445
The Abscopal Effect Associated With a Systemic Anti-melanoma Immune Response
Stamell, E. F., Wolchok, J. D., Gnjatic, S., Lee, N. Y., & Brownell, I. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.03.017 · Cited by 387
Knisely, J. P. S., Yu, J. B., Flanigan, J., Sznol, M., Kluger, H. M., & Chiang, V. L. S. (2012) · Journal of Neurosurgery · doi:10.3171/2012.5.jns111929 · Cited by 330
Takeshima, T., Chamoto, K., Wakita, D., Ohkuri, T., Togashi, Y., Shirato, H., Kitamura, H., & Nishimura, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2982 · Cited by 243
Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery
Mathew, M., Tam, M., Ott, P. A., Pavlick, A. C., Rush, S. C., Donahue, B. R., Golfinos, J. G., Parker, E. C., Huang, P. P., & Narayana, A. (2013) · Melanoma Research · doi:10.1097/cmr.0b013e32835f3d90 · Cited by 178
Outcome predictors of Gamma Knife surgery for melanoma brain metastases
Liew, D. N., Kano, H., Kondziolka, D. S., Mathieu, D., Niranjan, A., Flíckinger, J. C., Kirkwood, J. M., Tarhini, A. A., Moschos, S. J., & Lunsford, L. D. (2010) · Journal of neurosurgery · doi:10.3171/2010.5.jns1014 · Cited by 156
The Tumor-Immune Microenvironment and Response to Radiation Therapy
Shiao, S. L., & Coussens, L. M. (2010) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-010-9194-9 · Cited by 127
Safety and clinical activity of ipilimumab in melanoma patients with brain metastases
Weber, J. S., Amin, A., Minor, D. R., Siegel, J., Berman, D., & O'Day, S. J. (2011) · Melanoma Research · doi:10.1097/cmr.0b013e32834d3d88 · Cited by 113
NK and CD4 Cells Collaborate to Protect against Melanoma Tumor Formation in the Brain
Prins, R. M., Vo, D. D., Khan-Farooqi, H., Yang, M., Soto, H., Economou, J. S., Liau, L. M., & Ribas, A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.12.8448 · Cited by 63
Radiation-induced tumor neoantigens: imaging and therapeutic implications.
Corso, C. D., Ali, A. N., & Díaz, R. (2011) · Europe PMC (PubMed Central) · Cited by 59
Four, S. D., Wilgenhof, S., Duerinck, J., Michotte, A., Vanbinst, A., Ridder, M. D., & Neyns, B. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.05.016 · Cited by 53
Pathologic and gene expression features of metastatic melanomas to the brain
Hamilton, R. L., Krauze, M. T., Romkes, M., Omolo, B., Konstantinopoulos, P. A., Reinhart, T. A., Harasymczuk, M., Wang, Y., Lin, Y., Ferrone, S., et al. (2013) · Cancer · doi:10.1002/cncr.28029 · Cited by 50
Concurrent whole brain radiotherapy and bortezomib for brain metastasis
Lao, C. D., Friedman, J. D., Tsien, C. I., Normolle, D. P., Chapman, C. H., Cao, Y., Lee, O., Schipper, M. J., Poznak, C. H. V., Hamstra, D. A., et al. (2013) · Radiation Oncology · doi:10.1186/1748-717x-8-204 · Cited by 18
Self-citation
Cited by
Kim, J. E., Patel, M. A., Mangraviti, A., Kim, E. S., Theodros, D., Velarde, E., Liu, A., Sankey, E. W., Tam, A., Xu, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1535 · Cited by 461
Sahgal, A., Aoyama, H., Kocher, M., Neupane, B., Collette, S., Tago, M., Shaw, P., Beyene, J., & Chang, E. L. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.10.024 · Cited by 420
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
Bernstein, M. B., Krishnan, S., Hodge, J. W., & Chang, J. Y. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.30 · Cited by 399
Brain metastases: epidemiology
(2018) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-811161-1.00002-5 · Cited by 336
Chen, L., Douglass, J., Kleinberg, L., Ye, X., Marciscano, A. E., Forde, P. M., Brahmer, J., Lipson, E., Sharfman, W., Hammers, H., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.11.041 · Cited by 329
Metadata
- Authors
- Silk, A. W., Bassetti, M. F., West, B. T., Tsien, C. I., & Lao, C. D.
- Venue
- Cancer Medicine
- Publisher
- Wiley
- Published
- 2013-10-10
- Volume
- 2
- Issue
- 6
- Pages
- 899-906
- ISSN
- 2045-7634 (ISSN-L)
- OpenAlex
- W1974499786
- Cited by
- 280
- References
- 26
- FWCI
- 16.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.